Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
Meanwhile, Tango tries again in PRMT5.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Halda, Accent and Vividion take more projects into phase 1.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Opdualag chalks up another failure, this time in the extension of an approved use.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
